Artiva Biotherapeutics, Inc.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) is a clinical-stage biotechnology company focused on developing cell therapies for patients with autoimmune diseases and chronic conditions. The company engineers allogeneic, off-the-shelf NK cell therapies, including its lead candidate AB-101, a non-genetically modified NK cell product designed to target and deplete autoreactive B cells; AB-201, an NK cell therapy engineered with a chimeric receptor targeting CD19 and CD20 antigens; and its CAR-NK pipeline targeting BCMA and GPRC5D for autoimmune and oncology indications. Artiva's platform leverages proprietary manufacturing processes for scalable NK cell production, serving autoimmune disorders such as systemic lupus erythematosus (SLE), rheumatoid arthritis, and pemphigus; it operates primarily in the United States with clinical trials conducted globally. Founded in 2018 and headquartered in San Diego, California, the company recently completed its initial public offering in October 2024, raising gross proceeds of approximately $167 million, and announced a strategic licensing agreement with Otsuka Pharmaceutical in 2024 for AB-201 development in Japan. In late 2024, Artiva initiated dosing in the Phase 1/2 Lukos trial for AB-101 in progressive multifocal leukoencephalopathy (PML) and expanded its manufacturing capacity through a new facility partnership. No subsidiaries or parent companies are reported.
Artiva Biotherapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
Artiva Biotherapeutics Highlights AlloNK® Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast Today
The $13 Million Company Teaching the Immune System to Hunt Cancer
Artiva Biotherapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
Artiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at EULAR 2026 Congress, Including Late-Breaking Oral Presentation Highlighting Clinical Efficacy Comparable to Autologous CAR T-Cell Therapy in Rheumatologic Diseases
Artiva Biotherapeutics Appoints Veteran Biotech Executive and Drug Developer Diego Miralles, M.D., as President and Head of Research and Development
Artiva Biotherapeutics: 'Buy' On AlloNK POC And FDA Phase 3 Alignment For Refractory RA
Artiva Biotherapeutics Stock Slides Despite Positive Trial Data
Artiva Biotherapeutics Announces Pricing of $300 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
Artiva Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights
Artiva Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights
Artiva Announces Positive Initial Clinical Data with AlloNK® Across Multiple Autoimmune Diseases and FDA Alignment to Initiate Phase 3 Registrational Trial in Rheumatoid Arthritis in 2026
Artiva Announces Positive Initial Clinical Data with AlloNK® Across Multiple Autoimmune Diseases and FDA Alignment to Initiate Phase 3 Registrational Trial in Rheumatoid Arthritis in 2026
Artiva Biotherapeutics Spotlights RA as Lead NK Cell Program, Eyes H1 Efficacy Data Catalyst at Needham
Artiva Biotherapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Sees Significant Decrease in Short Interest
Artiva Biotherapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights
Artiva Biotherapeutics to Participate in the TD Cowen 46th Annual Health Care Conference
Artiva Biotherapeutics Announces Appointment of Thad Huston as Chief Financial Officer and Award of Inducement Grant
Artiva Biotherapeutics Announces Appointment of Elaine Sorg to Board of Directors